Literature DB >> 16342279

Genotypic interaction between DRD4 and DAT1 loci is a high risk factor for attention-deficit/hyperactivity disorder in Chilean families.

Ximena Carrasco1, Paula Rothhammer, Mauricio Moraga, Hugo Henríquez, Ranajit Chakraborty, Francisco Aboitiz, Francisco Rothhammer.   

Abstract

Attention-deficit/hyperactivity disorder, ADHD [MIM 126452], is a common, highly heritable neurobiological disorder of childhood onset, characterized by hyperactivity, impulsiveness, and/or inattentiveness. As part of an ongoing study of ADHD, we carried out a family-based discordant sib-pair analysis to detect possible associations between dopamine receptor D4 (DRD4) and dopamine transporter 1 (DAT1) polymorphisms and ADHD in Chilean families. Both loci individually classified as homozygotes or heterozygotes for the DRD4 7-repeat and DAT1 10-repeat alleles, did not exhibit genotype frequency differences between affected children and their healthy siblings (Fisher's exact test P > 0.25 in both cases). However, the simultaneous presence of both DRD4 7-repeat heterozygosity and DAT1 10 allele homozygosity were significantly higher (34.6%) in cases (26), compared with their unaffected siblings (25) (4%; Fisher's exact test P = 0.0096; odds-ratio, OR = 12.71). Increased density of dopamine transporter in ADHD brains, along with abundance of 7-repeat D4 receptors in prefrontal cortex, which is impaired in ADHD patients, make the observed gene-gene interaction worthy of further incisive studies. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16342279     DOI: 10.1002/ajmg.b.30259

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  20 in total

Review 1.  Role of dopamine receptors in ADHD: a systematic meta-analysis.

Authors:  Jing Wu; Haifan Xiao; Hongjuan Sun; Li Zou; Ling-Qiang Zhu
Journal:  Mol Neurobiol       Date:  2012-05-19       Impact factor: 5.590

2.  Epistasis between neurochemical gene polymorphisms and risk for ADHD.

Authors:  Ricardo Segurado; Mark A Bellgrove; Francesca Manconi; Michael Gill; Ziarah Hawi
Journal:  Eur J Hum Genet       Date:  2011-02-02       Impact factor: 4.246

Review 3.  Molecular genetics of attention deficit hyperactivity disorder.

Authors:  Stephen V Faraone; Eric Mick
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 4.  Psychopathological aspects of dopaminergic gene polymorphisms in adolescence and young adulthood.

Authors:  Zsofia Nemoda; Anna Szekely; Maria Sasvari-Szekely
Journal:  Neurosci Biobehav Rev       Date:  2011-04-15       Impact factor: 8.989

5.  Norepinephrine transporter and catecholamine-O-methyltransferase gene variants and attention-deficit/hyperactivity disorder symptoms in adults.

Authors:  W Retz; M Rösler; C Kissling; S Wiemann; R Hünnerkopf; A Coogan; J Thome; C Freitag
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

Review 6.  ADHD and the DRD4 exon III 7-repeat polymorphism: an international meta-analysis.

Authors:  Aki Nikolaidis; Jeremy R Gray
Journal:  Soc Cogn Affect Neurosci       Date:  2009-12-17       Impact factor: 3.436

Review 7.  Molecular genetics of attention-deficit/hyperactivity disorder: an overview.

Authors:  Tobias Banaschewski; Katja Becker; Susann Scherag; Barbara Franke; David Coghill
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-02-10       Impact factor: 4.785

Review 8.  Molecular genetics of monoamine transporters: relevance to brain disorders.

Authors:  K Haddley; A S Vasiliou; F R Ali; U M Paredes; V J Bubb; J P Quinn
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

Review 9.  A neurogenetic approach to impulsivity.

Authors:  Eliza Congdon; Turhan Canli
Journal:  J Pers       Date:  2008-12

Review 10.  Candidate gene studies of ADHD: a meta-analytic review.

Authors:  Ian R Gizer; Courtney Ficks; Irwin D Waldman
Journal:  Hum Genet       Date:  2009-06-09       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.